Patents by Inventor Elizabeth WATSON
Elizabeth WATSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181725Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: November 22, 2022Publication date: June 15, 2023Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20230112031Abstract: Methods and systems for managing workloads in a distributed computing environment are disclosed. The distributed computing environment may include dedicated infrastructure for performing the workloads and on-demand infrastructure that may be used to perform the workloads with attached increment cost for performance of workloads. It may be preferable to host the workloads with the dedicated infrastructure. However, the dedicated infrastructure may not always have sufficient computing resources to host all of the workloads that are to be performed over time. The disclosed methods and system may provide for workload management by automating workload instantiation, migration, and resource expansion of dedicated infrastructure.Type: ApplicationFiled: October 9, 2021Publication date: April 13, 2023Inventors: RACHEL ELIZABETH WATSON-JONES, DEEDER AURONGZEB, ERIN KURUSZ
-
Publication number: 20230086859Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 29, 2022Publication date: March 23, 2023Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 11554169Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: GrantFiled: September 20, 2018Date of Patent: January 17, 2023Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Patent number: 11407790Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: April 30, 2020Date of Patent: August 9, 2022Assignee: HOOKIPA BIOTECH GMBHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Publication number: 20210275872Abstract: An apparatus for treating spasticity can include a splint configured to receive a patient wrist and hand including a wrist portion of the splint including a moveable closure configured to secure a wrist of the patient to the splint. A hand portion of the splint can be rigidly coupled to the wrist portion, wherein the hand portion can include a hand portion that is shaped to receive a palm of the patient's hand and an inflatable bladder can be coupled to the hand portion, wherein the inflatable bladder can be configured to expand against fingers of the patient's hand during inflation.Type: ApplicationFiled: March 9, 2021Publication date: September 9, 2021Inventors: Joanna D. Cao, Isabella Elizabeth Watson, Martha Grace Farrell, Lars Patrick Chen, Misbah Ahmad, Jack Patrick Vincent
-
Publication number: 20210024584Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses.Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: April 30, 2020Publication date: January 28, 2021Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 10669315Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: June 9, 2016Date of Patent: June 2, 2020Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Publication number: 20190247493Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: September 20, 2018Publication date: August 15, 2019Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Patent number: 10111945Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: GrantFiled: December 3, 2014Date of Patent: October 30, 2018Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20180179257Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 9, 2016Publication date: June 28, 2018Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 9682123Abstract: The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.Type: GrantFiled: December 22, 2014Date of Patent: June 20, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Rudolph L. Leibel, Kazuhisa Watanabe, Wendy K. Chung, Stuart G. Fischer, Charles Leduc, Elizabeth Watson, Maria Laura Cremona
-
Publication number: 20160296619Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: December 3, 2014Publication date: October 13, 2016Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuelaö Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mülbacher
-
Publication number: 20150190466Abstract: The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.Type: ApplicationFiled: December 22, 2014Publication date: July 9, 2015Inventors: Rudolph L. LEIBEL, Kazuhisa WATANABE, Wendy K. CHUNG, Stuart G. FISCHER, Charles LEDUC, Elizabeth WATSON, Maria Laura CREMONA
-
Patent number: 8906066Abstract: Methods for non-pedicle spinal fixation. In some implementations, at least one plate member may be placed between an upper spinous process and a lower spinous process of a spine. At least one scissoring element coupled to the at least one plate member may then be positioned to contact opposing lateral surfaces of the upper spinous process and to contact opposing lateral surfaces of the lower spinous process. The at least one scissoring element may then be locked into place to stabilize the spinous processes.Type: GrantFiled: January 28, 2013Date of Patent: December 9, 2014Assignee: US Spine, Inc.Inventor: Elizabeth Watson Edmond
-
Publication number: 20130261669Abstract: Methods for non-pedicle spinal fixation. In some implementations, at least one plate member may be placed between an upper spinous process and a lower spinous process of a spine. At least one scissoring element coupled to the at least one plate member may then be positioned to contact opposing lateral surfaces of the upper spinous process and to contact opposing lateral surfaces of the lower spinous process. The at least one scissoring element may then be locked into place to stabilize the spinous processes.Type: ApplicationFiled: January 28, 2013Publication date: October 3, 2013Applicant: US SPINE, INC.Inventor: Elizabeth Watson Edmond
-
Patent number: 8361116Abstract: Spinal distraction apparatus includes at least one plate member having upper and lower surfaces adapted for placement between opposing upper and lower spinous processes having outer lateral surfaces. A pair of scissoring elements are hingedly affixed to the plate member to engage with the lateral surfaces of the spinous processes. A device is provided for locking the scissoring elements in position once a desired degree of contact is made. In a preferred configuration, the scissoring elements are sandwiched between a pair of opposing plate members, each having upper and lower surfaces adapted for placement between opposing upper and lower spinous processes, and the inner surfaces of the scissoring elements are concave. The device for locking the scissoring elements in position is a fastener that extends through a central portion of both scissoring elements and the plate members.Type: GrantFiled: March 26, 2007Date of Patent: January 29, 2013Assignee: U.S. Spine, Inc.Inventor: Elizabeth Watson Edmond